Barinthus Biotherapeutics plc
BRNS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $111 | $142 | $194 | $214 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $13 | $8 | $18 | $12 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $2 | $7 | $1 | $1 |
| Total Curr. Assets | $126 | $157 | $213 | $227 |
| Property Plant & Equip (Net) | $12 | $19 | $16 | $9 |
| Goodwill | $0 | $12 | $12 | $13 |
| Intangibles | $22 | $25 | $28 | $31 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $1 | $1 |
| Total NC Assets | $35 | $58 | $57 | $54 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $160 | $215 | $270 | $281 |
| Liabilities | – | – | – | – |
| Payables | $2 | $2 | $4 | $2 |
| Short-Term Debt | $2 | $2 | $0 | $1 |
| Tax Payable | $2 | $0 | $0 | $0 |
| Deferred Revenue | $2 | $0 | $0 | $0 |
| Other Curr. Liab. | $7 | $9 | $8 | $8 |
| Total Curr. Liab. | $16 | $13 | $12 | $11 |
| LT Debt | $10 | $11 | $8 | $7 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $1 | $4 | $8 |
| Other NC Liab. | $4 | $3 | $3 | $2 |
| Total NC Liab. | $15 | $15 | $15 | $17 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $12 | $13 | $9 | $7 |
| Total Liabilities | $30 | $28 | $27 | $28 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$238 | -$177 | -$103 | -$109 |
| AOCI | -$26 | -$23 | -$33 | -$8 |
| Other Equity | $394 | $387 | $380 | $369 |
| Total Equity | $130 | $187 | $243 | $252 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $160 | $215 | $270 | $281 |
| Net Debt | -$99 | -$129 | -$186 | -$207 |